Interferon Gamma
Mechanism :
Interferons are a family of naturally occurring proteins, which have molecular weights ranging from 15,000 to 21,000 daltons. Three major classes of interferons have been identified: alfa, beta, and gamma. Interferon beta-1b, interferon alfa, and interferon gamma have overlapping yet distinct biologic activities.
Indication :
- Chronic granulomatous disease
Contraindications :
Contraindicated in patients who have hypersensitivity to interferon gamma or known hypersensitivity to closely related interferons. Use with caution in seizure disorders and/or compromised CNS function; pre-existing cardiac disease, e.g. ischemia, congestive heart failure and arrhythmias; severe hepatic or renal impairment. Monitor before and during treatment; hematological tests (including FBC, differential white cell count and platelet count), blood chemistry tests (including renal and liver function tests) and urinalysis.
Dosing :
For Body Surface Area >0.5 m²:
50 microgram per m² given subcutaneously thrice a week.
For Body Surface Area <0.5 m²:
1.5 microgram per m² given subcutaneously thrice a week.
Adverse Effect :
Commonly reported adverse effects are fever, headache, chills, myalgia or fatigue, diarrhea, nausea and vomiting, arthralgia, rashes and injection-site reactions.
Interaction :
Serum protein preparations or immunological preparations (e.g. vaccines): Simultaneous administration should be avoided because of the risk for unexpected amplified immune response.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | No data on use in renal impairment. Dose as for normal renal function and monitor renal function closely |
| 10-20 | No data on use in renal impairment. Dose as for normal renal function and monitor renal function closely |
| <10 | Use with caution due to risk of accumulation. Monitor renal function closely |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Not dialysed. Dose as in GFR<10 mL/min |
| HD | Not dialysed. Dose as in GFR<10 mL/min |
| HDF/High flux | Dialysed. Dose as in GFR<10 mL/ min |
| CAV/VVHD | Unlikely dialysability. Dose as in GFR=10–20 mL/min |
Hepatic Dose :
There are no dosage adjustments provided in the manufacturer’s labeling; drug accumulation may occur in patients with advanced hepatic disease. If severe transaminase elevations occur during treatment, interrupt and reduce the dose upon resolution.